Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:5515 |
Name | nasal cavity squamous cell carcinoma |
Definition | A nasal cavity carcinoma that has_material_basis_in squamous cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer respiratory system cancer nasal cavity cancer nasal cavity squamous cell carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02538510 | Phase Ib/II | Pembrolizumab + Vorinostat | Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer and Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT03238365 | Phase I | Nivolumab + Tadalafil Nivolumab | Nivolumab With or Without Tadalafil in Treating Patients With Recurrent Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery | Completed | USA | 0 |
NCT05057247 | Phase II | Docetaxel + Duvelisib | Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC | Active, not recruiting | USA | 0 |
NCT06239220 | Phase II | Cetuximab + Nogapendekin alfa inbakicept + PD-L1.t-haNK cells | PD-L1 t-haNK, N-803 IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC | Recruiting | USA | 0 |
NCT06332092 | Phase II | Cetuximab + FID-007 | FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) | Recruiting | USA | 0 |